Prevalence of Multiple Sclerosis in Bogotá, ColombiaToro J.a-c · Sarmiento O.L.b · Díaz del Castillo A.a · Satizábal C.L.a, b · Ramírez J.D.a, c · Montenegro A.C.a, c · Góngora M.C.a · Quiñones J.A.a, c · Díaz A.a, c · Tobón A.a, c
aDepartment of Neurology, Fundación Santa Fe de Bogotá, bSchool of Medicine, Universidad de Los Andes, and cSchool of Medicine, Universidad El Bosque, Bogotá, Colombia
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Among Latin American countries, Colombia is considered a low-risk area for multiple sclerosis (MS) and no studies on MS prevalence have been conducted in any of the country’s large urban settings. To fill this gap and assess the prevalence of MS in Bogotá as of December 31, 2002, this study reviewed the clinical records of patients diagnosed with MS in most Bogotá hospitals. This review produced a sample of 296 patients with an MS diagnosis whose reliability was verified by a neurologist with expertise in MS. The total prevalence rate identified for December 2002 was 4.41/100,000 inhabitants (95% CI 3.9–4.9), including a rate of 5.98/100,000 (95% CI 5.2–6.8) for women and 2.71/100,000 (95% CI 2.2–3.3) for men (differences measured at p < 0.001). The prevalence estimates for Bogotá, confirm the city’s status as a low-risk area for MS.
© 2007 S. Karger AG, Basel
- Kurtzke JF: A reassessment of the distribution of multiple sclerosis. Acta Neurol Scand 1975;51:137–157.
- Pugliatti M, Sotgiu S, Rosati G: The worldwide prevalence of multiple sclerosis. Clin Neurol Neurosurg 2002;104:182–191.
- Rosati G: The prevalence of multiple sclerosis in the world: an update. Neurol Sci 2001;22:117–139.
- Hernandez-Valero E, Cabrera-Gomez JA, Valenzuela C: Clinical features of multiple sclerosis in western Cuba. A comparison with two other regions in the country (in Spanish). Rev Neurol 2004;38:818–823.
- Callegaro D, de Lolio CA, Radvany J, Tilbery CP, Mendonca RA, Melo AC: Prevalence of multiple sclerosis in the city of Sao Paulo, Brazil, in 1990. Neuroepidemiology 1992;11:11–14.
- Callegaro D, Goldbaum M, Morais L, Tilbery CP, Moreira MA, Gabbai AA, Scaff M: The prevalence of multiple sclerosis in the city of Sao Paulo, Brazil, 1997. Acta Neurol Scand 2001;104:208–213.
- Aguilar Rebolledo F, Estanol Vidal B, del Angel Torres A, Cabanas Garcia A, Lopes Rios G, Benitez L: Multiple sclerosis: clinical, paraclinical study and management of 24 cases (in Spanish). Rev Invest Clin 1985;37:231–235.
- Sanchez JL, Aguirre C, Arcos-Burgos OM, Jimenez I JM, Leon F, Pareja J, Pradilla G, Uribe B, Uribe CS, Villa A, Volcy M, Palacio LG: Prevalence of multiple sclerosis in Colombia (in Spanish). Rev Neurol 2000;31:1101–1103.
http://www.saludcapital.gov.co/secsalud/estadisticas (November 21, 2005).
- Castaño RA, Arbelaez JJ, Giedion UB, Morales LG: Equitable financing, out-of-pocket payments and the role of health care reform in Colombia. Health Policy Plan 2002;17:5–11.
http://www.bogota-dc.com/history/bog-his.htm (November 21, 2005).
http://www.dane.gov.co/index.php?option =com_content&task=category§ionid=23&id=185&Itemid=383# (March 6, 2006).
- Mckeown A: Global migration, 1846–1940. J World History 2004;15:155–189.
htpp://www.faculty.econ.nortwestern.edu/faculty/bernal/Health and Race june 22.pdf (February 2, 2006).
- McDonald WI, Compston A, Edan G, Gookin D, Hartung H, Lublin F, McFarland H, Paty D, Polman C, Reingold S, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker B, Wolinsky J: Recommended diagnostic criteria for multiple sclerosis: guideliness from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001;50:121–127.
- Poser CM, Brinar VV: The nature of multiple sclerosis. Clin Neurol Neurosurg 2004;106:159–171.
Cytel Software Corporation: StatXact Manual Version 7.0. Cambridge, Cytel Software, 2005.
Banks J, Carson J, Nelson B, Nicol D: Discrete-Event System Simulation, ed 3. Engelwood Cliffs, Prentice Hall, 2001.
SAS Institute Inc: SAS/STAT User’s Guide Version 8.2, ed 4. Cary, SAS Institute, 2000.
http://www.minproteccionsocial.gov.co/MseContent/NewsDetail.asp?ID=13482&IDCompany=24 (January 3, 2006).
- Kurtzke JF: A reassessment of the distribution of multiple sclerosis. Part one. Acta Neurol Scand 1975;51:110–136.
- McDonnell GV, Hawkins SA: An epidemiologic study of multiple sclerosis in Northern Ireland. Neurology 1998;50:423–428.
- Dahl OP, Aarseth JH, Myhr KM, Nyland H, Midgard R: Multiple sclerosis in Nord-Trondelag County, Norway: a prevalence and incidence study. Acta Neurol Scand 2004;109:378–384.
- Lublin FD, Reingold SC: Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907–911.
- Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG: Multiple sclerosis. N Engl J Med 2000;343:938–952.
- Mayr WT, Pittock SJ, McClelland RL, Jorgensen NW, Noseworthy JH, Rodriguez M: Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985–2000. Neurology 2003;61:1373–1377.
Ruggieri M, Ianetti P, Polizzi A, Pavone L, Grimaldi LME: Multiple sclerosis in children under 10 years of age. Neurol Sci 2004;25:S326–S335.
Christensen J: Multiple sclerosis: some epidemiological clues to its etiology. Acta Neurol Latinoamer 1975;21:66–85.
Grainger R, Allison D, Adam A, Dixon A: Magnetic resonance imaging: basic principles; in Grainger R, Allison D, Adam A, Dixon A, Carty H, Sprig A (eds): Grainger & Allison’s Diagnostic Radiology: A Textbook of Medical Imaging. Edinburgh, Churchill Livingstone, 2001, pp 101–136.
- Kurtzke JF: Epidemiology and multiple sclerosis. Rev Neurol 2002;35:1177.
http://www.minproteccionsocial.gov.co/MseContent/NewsDetail.asp?ID=13482&IDCompany=24 (February 7, 2006).
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.